drugset / Trial / NCT05913804
YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma
Phase 1
Recruiting
12 enrolled
Institute of Hematology & Blood Diseases Hospital, China
China Immunotech (Beijing) Biotechnology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, single-arm, open-label phase I clinical study to determine the safety and efficacy of relapsed or refractory multiple myeloma subjects
Timeline
- Start
- 2023-06-28
- Primary completion
- 2025-12-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YTS104 | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | YTS104 | Cell therapy | 3e+06 cells/kg | Intravenous |
| Subject | YTS104 | Cell therapy | 6e+06 cells/kg | Intravenous |
| Subject | YTS104 | Cell therapy | 1e+07 cells/kg | Intravenous |